Bruker Corporation (BRKR) stock price, news, quote and history
This article provides a comprehensive overview of Bruker Corporation (BRKR), including its current stock price, financial performance metrics, and analyst ratings. It details the company's business segments in scientific instruments and analytical solutions, along with key financial data such as market capitalization, earnings per share, and revenue. The article also includes historical performance data, earnings trends, and a comparison with the S&P 500 benchmark.
Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
Bruker Corporation announced new timsUltra AIP and timsOmni workflows at the Human Proteome Organization World Congress 2026. These advancements aim to enhance protein-sequence coverage, targeted validation, glycopeptide characterization, structural proteomics, and oligonucleotide analysis. The new workflows facilitate deeper understanding of proteoforms, protein interactions, and nucleic acids, contributing to drug discovery, disease biology research, and the development of next-generation biological AI models.
Arm leads Wednesday's losers with an 8.5% drop as Bruker tops the gainers
On Wednesday, September 24, Arm experienced the steepest decline among 111 priority stocks, dropping 8.5%, while Bruker led the gainers with a 7.5% increase. Other notable movers included Tempus AI and IonQ on the upside, and Digital Turbine, GoPro, General Motors, and SanDisk among the decliners. The article also touches upon Meta's significant positive close and the spread of gains and losses across various sectors.
UC Berkeley orders more than $6 million in research equipment from Bruker
Bruker Corporation announced a multi-system order exceeding $6 million from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation. This investment, expected to be delivered in 2027, will significantly upgrade the Pines Magnetic Resonance Center, enhancing research capabilities in various scientific fields. The new equipment, including an AV NEO-X 800 MHz spectrometer, aims to propel UC Berkeley to the forefront of innovation in magnetic resonance.
Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley
Bruker Corporation announced a multi-system order from the University of California, Berkeley, for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. This investment, exceeding $6 million, will enhance UC Berkeley's research capabilities in chemistry, materials science, structural biology, and related fields by integrating next-generation NMR technologies, including an 800 MHz AV NEO-X spectrometer and MAS CryoProbe. The new systems are expected to be delivered in 2027, bolstering the center's ability to conduct multidisciplinary studies on molecular structure and dynamics.
Bruker (BRKR) EVP sells 2,000 shares under trading plan
Mark Munch, EVP and President of Bruker Nano Inc., an executive at Bruker Corp (BRKR), exercised stock options for 2,000 shares and subsequently sold all of them on September 15, 2026. The transaction was conducted under a Rule 10b5-1 trading plan. He exercised the options at $22.19 per share and sold the shares at $52.87 per share, resulting in an approximate pre-tax spread of $61,000.
Bruker (NASDAQ: BRKR) officer to sell 2,000 shares
Bruker Corporation officer Mark R. Munch has filed a Rule 144 notice to sell 2,000 shares of BRKR common stock, valued at approximately $105,740. This planned sale follows similar recent sales by Munch of 2,000 shares each in July and August 2026. The shares to be sold originated from a stock option exercise, and the transaction will be executed through Morgan Stanley Smith Barney on NASDAQ.
Bruker at Wells Fargo Healthcare Conference: deep tech drives growth
Bruker Corporation outlined its business strategy at the Wells Fargo Healthcare Conference, highlighting strong demand in "deep tech" sectors like semiconductor metrology, defense, and fusion research, which are driving growth despite longer delivery cycles. The company also detailed its strategic shifts in life sciences, including the integration of AI and acquisitions like Mimetas, and discussed promising opportunities in proteomics. While facing near-term headwinds from AI infrastructure spending in life sciences, Bruker remains confident in future growth driven by innovation and strategic market positioning.
Bruker Corp (BRKR) Shares Fall 4.3% -- What GF Score of 84 Tells Investors
Bruker Corp (BRKR) shares dropped 4.3% to $56.98, yet its GF Score of 84/100 indicates strong overall performance. The stock is considered slightly undervalued with a GF Value of $60.24, despite unprofitability and recent insider selling worth $3.6 million. Investors are advised to exercise caution and conduct further evaluation due to these mixed signals.
Barclays Maintains Bruker Corp(BRKR.US) With Buy Rating, Cuts Target Price to $58
Barclays has reiterated its Buy rating for Bruker Corp (BRKR.US) but has adjusted its price target downwards to $58. This indicates a continued positive outlook on the company's stock despite a revision in its valuation.
Bruker Corp (XTER:BKD) Stock Price & 30 Year Financial Data
This article provides 30-year financial data for Bruker Corp (XTER:BKD), including key growth rates for revenue, EPS, EBIT, EBITDA, free cash flow, dividends, and book value. It details the company's current stock price, market capitalization, and various financial ratios. The page also outlines how GuruFocus calculates growth rates and presents options for viewing and exporting financial data.
Ceredex Value Advisors LLC Acquires Shares of 213,450 Bruker Corporation $BRKR
Ceredex Value Advisors LLC has acquired 213,450 shares of Bruker Corporation (NASDAQ:BRKR) valued at approximately $12.8 million. Other institutional investors also adjusted their positions, with hedge funds and institutional investors collectively owning 79.52% of the company. Bruker reported an EPS of $0.49, surpassing estimates, and declared a quarterly dividend of $0.05 per share, while analysts maintain a "Moderate Buy" rating with a target price of $56.64.
Advisors Capital Management LLC Purchases Shares of 81,937 Bruker Corporation $BRKR
Advisors Capital Management LLC has acquired a new position in Bruker Corporation, purchasing 81,937 shares valued at approximately $4.93 million. This makes them owners of about 0.05% of Bruker's stock. Other institutional investors have also adjusted their holdings, with significant increases from Orbis Allan Gray Ltd, Pallas Capital Advisors LLC, State Street Corp, AQR Capital Management LLC, and Sculptor Capital LP.
Bruker Corporation (NASDAQ:BRKR) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Bruker Corporation (NASDAQ:BRKR) has received a consensus "Moderate Buy" rating from fourteen brokerages, with an average 12-month price target of $56.64. The company recently exceeded earnings expectations with $0.49 EPS against a $0.38 consensus but fell short on revenue estimates, reporting $838.5 million. Several firms have adjusted their price targets, and Bruker also declared a quarterly dividend of $0.05 per share.
Trending Industry Today: Bruker Corp Leads Gains In Room-Temp Superconductors Stocks
The article discusses the trending industry of room-temperature superconductors, highlighting Bruker Corp as a leading gainer in this sector.
Old West Investment Management LLC Acquires Shares of 667,103 Bruker Corporation $BRKR
Old West Investment Management LLC has acquired a significant new stake of 667,103 shares in Bruker Corporation (NASDAQ:BRKR), valued at approximately $40.1 million. This makes Bruker its largest portfolio holding, representing 4.3% of its assets and about 0.44% of Bruker's total shares. Bruker recently reported strong quarterly earnings, beating EPS estimates, though revenue slightly missed expectations, while analysts hold a "Moderate Buy" consensus rating for the stock.
Bruker declares $0.05 quarterly dividend for common shareholders
Bruker Corporation (NASDAQ:BRKR) has declared a quarterly cash dividend of $0.05 per share, payable on October 7, 2026. This dividend results in a 0.35% yield and comes as the stock has seen a 73% gain over the past year. Despite strong shareholder yield, the stock is considered overvalued according to InvestingPro analysis, and the company recently surpassed profit expectations while revenue fell short.
Bruker Corp Executive Mark Munch Reports Share Withholding to Cover RSU Tax Obligations
Mark Munch, Executive Vice President and President of Bruker Nano Inc., disposed of 1,619 shares of Bruker Corp common stock on August 11, 2026, to cover tax withholding obligations associated with the vesting of restricted stock units. The shares, valued at $57.02 each, were withheld by the company. After this transaction, Munch directly owns 123,347 shares of Bruker Corp.
Bruker Announces Strategic Collaboration with Atinary Technologies to Advance Self-Driving Laboratories
Bruker Corporation announced an expanded strategic collaboration with Atinary Technologies Inc., a pioneer in Self-Driving Labs technologies and AI-driven R&D, which also includes a minority investment by Bruker. The collaboration aims to integrate Atinary's SDLabs platform with Chemspeed automation and Bruker instruments to create closed-loop, AI-driven R&D workflows for accelerated scientific discovery. This initiative will enable scientists to use AI agents for designing experiments, navigating molecular spaces, and interpreting results, thereby accelerating the development of new molecules and materials.
J.P. Morgan Maintains Bruker Corp(BRKR.US) With Buy Rating, Cuts Target Price to $60
J.P. Morgan has reiterated its Buy rating on Bruker Corp (BRKR.US) but has revised its target price downwards to $60. This adjustment reflects J.P. Morgan's updated valuation for the company while maintaining a positive outlook on its stock.
Bruker takes majority stake in organ-on-a-chip firm MIMETAS
Bruker Corporation has acquired a majority stake in MIMETAS B.V., a company specializing in organ-on-a-chip platforms and human tissue models for drug discovery. This investment will allow Bruker to integrate MIMETAS' OrganoPlate platform with its existing technologies, expanding its offerings in Microphysiological Systems. MIMETAS will continue to operate under its current brand and management.
Bruker Announces Majority Investment in MIMETAS to Advance Human Physiology-Relevant Drug Discovery and Development
Bruker Corporation announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue models. This investment aims to expand Bruker's post-genomic solutions for disease biology research and drug discovery into Microphysiological Systems (MPS). The collaboration will combine MIMETAS's OrganoPlate® platform with Bruker's technologies to offer integrated workflows for disease research, compound evaluation, and drug development.
J.P. Morgan Maintains Bruker Corp(BRKR.US) With Buy Rating, Cuts Target Price to $60
J.P. Morgan has reiterated its "Buy" rating on Bruker Corp (BRKR.US) but has lowered the price target for the stock to $60. This adjustment reflects a revised outlook from the analyst firm while maintaining a positive investment stance on the company.
Amundi Increases Stock Position in Bruker Corporation $BRKR
Amundi increased its stake in Bruker Corporation (NASDAQ:BRKR) by 244.2% in the first quarter, now holding 62,611 shares valued at $2.26 million. Despite the company beating EPS estimates for Q2 2026 with $0.49 per share, its revenue of $838.5 million missed analyst expectations, raising concerns about demand and growth in its primary market. Analysts maintain a "Moderate Buy" consensus rating with a target price of $56.64, though some have lowered their targets due to revenue performance.
Bruker Corp (BRKR): FMR LLC and Abigail Johnson report 15% ownership
FMR LLC and Abigail P. Johnson have reported a 15.0% beneficial ownership stake in Bruker Corp (BRKR) common stock, as detailed in a Schedule 13G/A SEC filing. FMR LLC beneficially owns 23,296,465.55 shares, with sole voting power over 17,974,598.38 shares and sole dispositive power over all its shares. Abigail P. Johnson is also listed with beneficial ownership of 23,296,465.55 shares, holding sole dispositive power.
Bruker Corp (BRKR) Stock Up 4.3% and Still Undervalued -- GF Sco
Bruker Corp (BRKR) shares rose 4.3% to $52.47, trading below its GF Value™ of $62.94, suggesting it is undervalued despite being currently unprofitable and cash-flow negative. The company has a strong GF Score™ of 85/100, driven by good profitability and momentum, though its financial strength is moderate. While gurus are largely increasing their positions, insider selling raises some cautious signals for investors.
Citi Maintains Bruker Corp(BRKR.US) With Hold Rating, Cuts Target Price to $53
Citi has reiterated its Hold rating on Bruker Corp (BRKR.US) while simultaneously lowering its target price for the company's stock to $53. This adjustment reflects Citi's updated outlook for Bruker Corp.
Guggenheim Maintains Bruker Corp(BRKR.US) With Buy Rating, Maintains Target Price $70
Guggenheim has reiterated its Buy rating for Bruker Corp (BRKR.US), maintaining a target price of $70. This indicates a continued positive outlook from the firm regarding Bruker's stock performance and value.
Bruker Corp Q2 2026: Revenue $838.5M, EPS $(0.41) — 10-Q Summary
Bruker Corp reported its Q2 2026 results, showing a revenue increase to $838.5M from $797.4M a year prior. Despite this growth, the company recorded a net loss of $(62.9)M and diluted EPS of $(0.41), down from a net income of $7.6M and EPS of $0.05 in the year-ago quarter. Revenue growth was driven by demand in biotech, pharma, clinical, and semiconductor markets, though Asia Pacific saw a decline, and the company noted goodwill impairments and restructuring charges impacting its bottom line.
Is Bruker (BRKR) Fairly Valued After Its 52 Week High?
Bruker (BRKR) stock has seen significant growth over the past year, reaching a 52-week high, yet analysis suggests it remains undervalued. Discounted Cash Flow (DCF) models indicate the stock trades at approximately a 41.1% discount to its intrinsic value, while its Price/Sales (P/S) multiple of 2.2x is below the industry average of 4.2x. The article explores both bull and bear cases, highlighting opportunities from recurring revenue streams and risks from reliance on research funding.
Earnings call transcript: Bruker beats Q2 EPS forecast but shares sink on revenue miss, Q2 2026
Bruker Corp. reported Q2 2026 adjusted EPS of $0.49, exceeding the forecast of $0.3832, but revenue missed estimates at $838.5 million against an expected $853.39 million. Despite stronger margins, cost savings, and a return to organic revenue growth, the stock fell 16.82% due to the revenue miss and a cautious near-term outlook. The company maintained its full-year EPS guidance but adjusted foreign exchange assumptions, highlighting strong demand in biopharma, semiconductor metrology, and energy research, while U.S. academic and government spending remained weak.
Bruker: Q2 Earnings Snapshot
Bruker Corp. reported a second-quarter loss of $52 million, or 41 cents per share, which was a reversal from a profit in the same period last year. Despite the loss, adjusted earnings of 49 cents per share surpassed Wall Street expectations. The scientific equipment maker posted revenue of $838.5 million and provided full-year earnings and revenue guidance, with its shares showing significant growth over the past year.
Bruker Q2 2026 slides: margins surge but revenue miss triggers selloff
Bruker Corporation (NASDAQ:BRKR) reported Q2 2026 earnings with a significant surge in non-GAAP earnings per share and strong margin expansion, but a revenue miss against Wall Street expectations triggered an 18.13% stock selloff. Despite operational improvements and growth in key segments like semiconductor metrology, the revenue shortfall and a cautious near-term outlook overshadowed the profitability gains. Management maintained full-year guidance but adjusted assumptions for currency and tax impacts, acknowledging investor concerns about revenue growth sustainability.
Bruker Corporation Q2 2026 Earnings Call Summary
Bruker Corporation reported a pivot back to organic revenue growth in Q2 2026, driven by strong demand in "deep tech" sectors like semiconductor metrology and energy research, despite softness in the U.S. academic and government sectors. The company implemented a new four-group operating structure and is on track for significant cost savings and margin expansion, anticipating a strong Q4 and accelerated growth in 2027. Key factors include sustainable AI-driven demand, manageable helium supply risks, and a commitment to expanding operating margins.
Earnings call transcript: Bruker beats Q2 EPS forecast but shares sink on revenue miss, Q2 2026
Bruker Corp. reported mixed results for Q2 2026, beating EPS forecasts at $0.49 but missing revenue estimates at $838.5 million. Stronger margins and cost reductions, partially due to tariff refunds, bolstered profits, but lower-than-expected sales growth and a cautious near-term outlook led to a 16.82% drop in shares. The company maintained full-year EPS guidance but trimmed foreign exchange assumptions, highlighting strong demand in biopharma, semiconductor metrology, and energy research, while U.S. academic and government spending remained soft.
Bruker (BRKR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Bruker (BRKR) reported its Q2 2026 earnings, with revenues of $838.5 million, up 5.2% year-over-year, and EPS of $0.49, significantly higher than $0.32 in the prior year quarter. The company surpassed EPS estimates by 28.95% but missed revenue estimates by 2.18%. Key metrics like organic revenue growth for Bruker Energy & Supercon Technologies exceeded analyst expectations, contributing to the stock's recent outperformance against the S&P 500.
Bruker Reports Q2 2026 Revenue $838.5M; Non-GAAP EPS $0.49, Updates FY26 Guidance
Bruker reported its second-quarter 2026 results, with revenues of $838.5 million and non-GAAP diluted EPS of $0.49, despite a GAAP diluted loss per share of $(0.41) due to a non-cash goodwill impairment. The company also updated its full-year 2026 guidance for currency and tax, projecting revenues between $3.54 billion and $3.57 billion and non-GAAP EPS of $2.10 to $2.15. Key business highlights include strong organic bookings growth in Bruker Scientific Instruments and a focus on cost savings initiatives to drive margin expansion.
Bruker Corporation (Nasdaq: BRKR) posts $838.5M sales, EPS loss
Bruker Corporation reported Q2 2026 revenue of $838.5 million, a 5.2% year-over-year increase, but posted a GAAP diluted loss per share of $(0.41) due to a significant non-cash goodwill impairment charge of $134.9 million. Despite the GAAP loss, the company achieved positive non-GAAP diluted EPS of $0.49 and expanded its non-GAAP operating margin to 14.1%. Bruker also updated its full-year 2026 guidance, maintaining its non-GAAP EPS outlook and adjusting revenue expectations for currency and tax impacts.
Bruker Corp Q2 2026: Revenue $838.5M, EPS $(0.41) — 10-Q Summary
Bruker Corp reported its second-quarter 2026 financial results, with revenue increasing to $838.5M, up 5.2% year-over-year. Despite the revenue growth, the company recorded a net loss of $(62.9)M and diluted EPS of $(0.41), a significant decline from the previous year's net income. The report highlighted revenue drivers such as demand in biotech, pharma, clinical, and semiconductor markets, strong sales in North America and Europe, and impacts from recent acquisitions, while also noting challenges from Asia Pacific decline, FX headwinds, restructuring charges, and goodwill impairments.
Bruker Corporation stock hits 52-week high at 65.3 USD
Bruker Corporation (BRKR) stock reached a 52-week high of $65.3 USD, reflecting a significant 71.89% increase over the last 12 months. The company's performance is boosted by strategic acquisitions and strong demand in the semiconductor sector, leading analysts to reiterate "Buy" and "Outperform" ratings with price targets up to $70. However, InvestingPro's Fair Value analysis suggests the stock might be overvalued.
Bruker Corp (BRKR) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Bruker Corp (BRKR), detailing its current valuation score, P/E ratio, and ranking within the Healthcare Equipment & Supplies industry. It highlights that the company's P/E ratio is -268.08, significantly below its recent high and above its recent low. However, it notes that relevant data for P/E TTM, P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Bruker Corporation (Nasdaq: BRKR) sets $3.9844 dividend on Series A preferred
Bruker Corporation declared a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A, declared on July 30, 2026. The dividend is payable on September 1, 2026, to shareholders of record as of August 15, 2026. This action applies to the company's preferred shares and reflects the stated dividend rate.
Bruker Corp (BRKR) Institutional Confidence
Bruker Corp (BRKR) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 91.74%, a slight decrease from the previous quarter. Steven Cohen is the largest institutional shareholder, holding 0.63% of outstanding shares.
Earnings Preview: Bruker Corp to Report Financial Results Pre-market on August 04
Bruker Corp (BRKR) is scheduled to release its financial results pre-market on August 4, 2026. Analysts are projecting earnings per share (EPS) of $0.66, with revenue expected to be $730.29 million. Investors will be keen to see if the company beats these estimates.
Bruker Corp (BRKR) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Bruker Corp (BRKR), detailing its current risk score of 7.43, which ranks 39 out of 199 in the Healthcare Equipment & Supplies industry. It highlights the company's beta value of 1.24, indicating higher volatility compared to the S&P 500. The assessment covers various metrics including volatility, maximum drawdown, return-to-drawdown ratio, skewness, and liquidity.
Bruker Corp (BRKR) Financial Health: Profitability & Balance Sheet Analysis
Bruker Corp (BRKR) currently holds a financial score of 8.42, ranking 36 out of 199 in the Healthcare Equipment & Supplies industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue saw a 2.75% year-over-year increase, with net profit surging by 79.89%. Further detailed financial data regarding cash, assets, and profits have not yet been disclosed by the company.
Bruker Corp (BKD) Q1 2026 Earnings Report - Results, Call & Slides
Bruker Corp (BKD) announced its Q1 2026 earnings, beating both EPS and revenue expectations. While the company faces near-term challenges like organic revenue declines and academic funding weaknesses, it reconfirmed its full-year 2026 guidance, citing strong bookings, AI-driven opportunities, and cost savings exceeding original targets. The earnings call sentiment was cautiously constructive, highlighting operational momentum despite current headwinds.
Bruker Number of Employees 2026 | Employee Count & Headcount Data
As of March 2026, Bruker Corp. (NASDAQ: BRKR) has approximately 11,059 employees worldwide, representing a 0.6% growth since 2023 but a 1.2% decline year-over-year. The company, headquartered in Billerica, Massachusetts, is actively hiring, with 457 job postings in 2026, although hiring velocity has slowed. Key concentrations of its workforce are in the United States, Germany, and Switzerland, with India being its fastest-growing location, and the average salary is $78,156.
Bruker Corp (BRKR) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Bruker Corp (BRKR), including its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The analysis suggests the stock is currently trading within a range, making it suitable for range-bound swing trading, with most moving averages indicating a "Buy" signal.
Bruker Corp (BRKR) Stock Up 4.8% and Still Undervalued -- GF Sco
Bruker Corp (BRKR) shares recently rose by 4.8% to $62.91, placing the stock in a fairly valued category according to its GF Value™ of $62.89. Despite a strong GF Score™ of 86/100, the company faces concerns regarding its cash-flow-negative status, low financial strength (5/10), and insider selling activity. Investors are advised to proceed with caution due to these mixed signals and underlying financial weaknesses.
